
490 Biotech Inc Profile last edited on: 10/31/22
CAGE: 6H7R3
UEI: L2T9XGZ1JUL5
Business Identifier: Bio-luminescent human cell lines for data acquisition without substrate. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Knox
Congr. District: 02
County: Knox
Public Profile
490 BioTech is a life sciences company developing patented protected light-emitting (bioluminescent) human cell lines genetically programmed to âreportâ on biological events or interactions that affect their metabolic status. The firm's autobioluminescent technologies enable cells autonomously to control or continuously produce light without any external activation required. The Clinet User can choose pre-made, continuously luminescent human cell models, ready-to-use assay mixes that can make any cell glow for up to one week, robust, yeast-based environmental sensor kits, or custom solutions allow the User to garner more information with less cost and effort than ever before. The incorporation of these cell lines into cell culture and small animal preclinical efficacy/toxicity testing models does not require expensive substrates and as such is designed to accelerate the pace of new drug discovery and move drugs more rapidly and effectively towards Phase I human test
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 2 | NIH | $1,215,933 | |
Project Title: Expanding the Throughput of Real-Time Toxicological Screening of Cardiac Differentiation by Expressing a Synthetic Luciferase/Luciferin Genetic Pathway in Ipscs | ||||
2018 | 1 | NIH | $150,000 | |
Project Title: Autonomously-Activating Bioluminescent Reporters to Enable Continuous, Real-Time, Non-Invasive Brain Cell Imaging | ||||
2018 | 2 | NIH | $1,143,917 | |
Project Title: Expressing Humanized Bacterial Luciferase in Stem Cells: Moving Beyond Firefly Luciferase to Expand the Informational Capacity of Animal Models for Regenerative Medicine | ||||
2018 | 2 | NIH | $1,145,563 | |
Project Title: Development of a High-Throughput Screen to Detect the Effects of Both Pre- and Post-Biotransformed Compounds for Enhanced Content Drug Discovery Workflows | ||||
2016 | 2 | NIH | $1,133,944 | |
Project Title: Expressing Bacterial Bioluminescence in Human Cell Lines: Engineering Autobioluminescent Reporter Cells to Screen for Endocrine Disruptor Chemicals |
Key People / Management
Gary S Sayler -- CEO
Dan Close -- Co-Founder and Chief Scientific Officer
Dan Morrison
Stacey Patterson -- CTO
Steven Ripp -- COO
Mark Wienhold -- Research Scientist
Dan Close -- Co-Founder and Chief Scientific Officer
Dan Morrison
Stacey Patterson -- CTO
Steven Ripp -- COO
Mark Wienhold -- Research Scientist